Associations - ABCG2 overexpression

ABCG2 overexpression ABCG2 overexpression	Osteosarcoma Osteosarcoma	ABCG2 overexpression ABCG2 overexpression	Osteosarcoma Osteosarcoma	MAP Resistant: C3 – Early Trials	MAP Resistant: C3 – Early Trials
ABCG2 overexpression ABCG2 overexpression	Head and Neck Cancer Head and Neck Cancer	ABCG2 overexpression ABCG2 overexpression	Head and Neck Cancer Head and Neck Cancer	paclitaxel Resistant: C3 – Early Trials	paclitaxel Resistant: C3 – Early Trials
ABCG2 overexpression ABCG2 overexpression	Breast Cancer Breast Cancer	ABCG2 overexpression ABCG2 overexpression	Breast Cancer Breast Cancer	paclitaxel Resistant: D – Preclinical	paclitaxel Resistant: D – Preclinical
ABCG2 overexpression ABCG2 overexpression	Colorectal Cancer CRC	ABCG2 overexpression ABCG2 overexpression	Colorectal Cancer CRC	oxaliplatin Resistant: D – Preclinical	oxaliplatin Resistant: D – Preclinical
ABCG2 overexpression ABCG2 overexpression	Colorectal Cancer CRC	ABCG2 overexpression ABCG2 overexpression	Colorectal Cancer CRC	PF-05212384 Resistant: D – Preclinical	PF-05212384 Resistant: D – Preclinical
ABCG2 overexpression ABCG2 overexpression	Solid Tumor Solid Tumor	ABCG2 overexpression ABCG2 overexpression	Solid Tumor Solid Tumor	TP-3654 + IT-141 Sensitive: D – Preclinical	TP-3654 + IT-141 Sensitive: D – Preclinical
ABCG2 overexpression ABCG2 overexpression	Solid Tumor Solid Tumor	ABCG2 overexpression ABCG2 overexpression	Solid Tumor Solid Tumor	mitoxantrone + TP-3654 Sensitive: D – Preclinical	mitoxantrone + TP-3654 Sensitive: D – Preclinical
ABCG2 overexpression ABCG2 overexpression	Solid Tumor Solid Tumor	ABCG2 overexpression ABCG2 overexpression	Solid Tumor Solid Tumor	topotecan + TP-3654 Sensitive: D – Preclinical	topotecan + TP-3654 Sensitive: D – Preclinical